{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:34:26Z","timestamp":1792737266411,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.clim.2011.11.010","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T03:09:07Z","timestamp":1323486547000},"page":"320-331","source":"Crossref","is-referenced-by-count":75,"title":["Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo"],"prefix":"10.1016","volume":"142","author":[{"given":"Leonard","family":"Moise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"De Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2011.11.010_bb0005","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"92","author":"Lenting","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0010","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1074\/jbc.274.22.15401","article-title":"The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity","volume":"274","author":"Fay","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2011.11.010_bb0015","doi-asserted-by":"crossref","first-page":"29826","DOI":"10.1074\/jbc.274.42.29826","article-title":"Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa","volume":"274","author":"Fay","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2011.11.010_bb0020","doi-asserted-by":"crossref","first-page":"27087","DOI":"10.1074\/jbc.270.45.27087","article-title":"Localization of factor IXa and factor VIIIa interactive sites","volume":"270","author":"O'Brien","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2011.11.010_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","article-title":"The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A","volume":"9","author":"Lusher","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.clim.2011.11.010_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2516.2002.00624.x","article-title":"Pathophysiology of inhibitors to factor VIII in patients with haemophilia A","volume":"8","author":"Lacroix-Desmazes","year":"2002","journal-title":"Haemophilia"},{"issue":"Suppl. 4","key":"10.1016\/j.clim.2011.11.010_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2516.2004.01009.x","article-title":"Inhibitors in haemophilia: pathophysiology","volume":"10","author":"Saint-Remy","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.clim.2011.11.010_bb0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1537-2995.1989.29589284147.x","article-title":"Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC","volume":"29","author":"Ragni","year":"1989","journal-title":"Transfusion"},{"key":"10.1016\/j.clim.2011.11.010_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/367425a0","article-title":"How B and T cells talk to each other","volume":"367","author":"Clark","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.clim.2011.11.010_bb0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1055\/s-0037-1616733","article-title":"Blockade of CD40\/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance","volume":"86","author":"Reipert","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0055","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/eji.1830230948","article-title":"Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction","volume":"23","author":"Holder","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2011.11.010_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/08830189709068169","article-title":"CD40: a pivotal receptor in the determination of life\/death decisions in B lymphocytes","volume":"15","author":"Klaus","year":"1997","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.clim.2011.11.010_bb0065","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/1521-4141(200009)30:9<2548::AID-IMMU2548>3.0.CO;2-H","article-title":"Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer","volume":"30","author":"Qian","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2011.11.010_bb0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1160\/TH05-02-0118","article-title":"Anti-factor VIII antibodies: a 2005 update","volume":"94","author":"Lavigne-Lissalde","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0075","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1160\/TH03-12-0755","article-title":"Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site","volume":"92","author":"Pratt","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0080","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V92.10.3701","article-title":"Residues Glu2181\u2013Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII","volume":"92","author":"Healey","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0085","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","article-title":"Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site","volume":"86","author":"Scandella","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0090","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0095","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2004.00918.x","article-title":"T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects","volume":"2","author":"Hu","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0100","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0105","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/blood-2008-10-186452","article-title":"A role for thrombin in the initiation of the immune response to therapeutic factor VIII","volume":"114","author":"Skupsky","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0110","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.11.010_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2002-32664","article-title":"Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products","volume":"28","author":"Kreuz","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2011.11.010_bb0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V95.2.564","article-title":"Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human\/porcine factor VIII molecules","volume":"95","author":"Barrow","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V75.2.378.378","article-title":"Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients","volume":"75","author":"Nilsson","year":"1990","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2011.11.010_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000056717","article-title":"Induction of immune tolerance in haemophilia A inhibitor patients by the \u2018Bonn Protocol\u2019: predictive parameter for therapy duration and outcome","volume":"77","author":"Oldenburg","year":"1999","journal-title":"Vox Sang."},{"key":"10.1016\/j.clim.2011.11.010_bb0145","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0150","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0155","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0160","first-page":"171","article-title":"De-immunization of therapeutic proteins by T-cell epitope modification","volume":"122","author":"De Groot","year":"2005","journal-title":"Dev. Biol. (Basel)"},{"key":"10.1016\/j.clim.2011.11.010_bb0165","first-page":"332","article-title":"Prediction of immunogenicity for therapeutic proteins: state of the art","volume":"10","author":"De Groot","year":"2007","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.clim.2011.11.010_bb0170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1055\/s-0037-1613064","article-title":"Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling","volume":"87","author":"Warmerdam","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0175","first-page":"1030","article-title":"De-immunization of human factor VIII: identification of epitopes in the C2 domain","volume":"112","author":"Moise","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clim.2011.11.010_bb0180","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0264-410X(98)00173-X","article-title":"Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix","volume":"16","author":"Schafer","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2011.11.010_bb0185","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/aid.1997.13.529","article-title":"An interactive web site providing major histocompatibility ligand predictions: application to HIV research","volume":"13","author":"De Groot","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.clim.2011.11.010_bb0190","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","article-title":"Several common HLA-DR types share largely overlapping peptide binding repertoires","volume":"160","author":"Southwood","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2011.11.010_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1359-6446(05)03720-7","article-title":"Immunomics: discovering new targets for vaccines and therapeutics","volume":"11","author":"De Groot","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.clim.2011.11.010_bb0200","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20052471","article-title":"Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide","volume":"203","author":"Steere","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2011.11.010_bb0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2011.11.010_bb0210","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V95.4.1324.004k25_1324_1329","article-title":"Prevention and treatment of factor VIII inhibitors in murine hemophilia A","volume":"95","author":"Qian","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0896-8411(03)00120-3","article-title":"Characterization of HLA DR2 and DQ8 transgenic mouse with a new engineered mouse class II deletion, which lacks all endogenous class II genes","volume":"21","author":"Cheng","year":"2003","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2011.11.010_bb0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1196\/annals.1394.005","article-title":"A new humanized HLA transgenic mouse model of multiple sclerosis expressing class II on mouse CD4 T cells","volume":"1103","author":"Mangalam","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clim.2011.11.010_bb0225","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2004-11-4274","article-title":"Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins","volume":"105","author":"Lei","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0230","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.11.010_bb0235","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2011.11.010_bb0245","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V95.2.558","article-title":"Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes","volume":"95","author":"van Den Brink","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.11.010_bb0255","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.V99.8.2828","article-title":"Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII","volume":"99","author":"van den Brink","year":"2002","journal-title":"Blood"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611003391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611003391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T17:47:00Z","timestamp":1686505620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661611003391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1521661611003391"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2011.11.010","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}